Altundag, O. Et Al. 2004. DNA methylation inhibitor, procainamide, may decrease the tamoxifen resistance by inducing overexpression of the estrogen receptor beta in breast cancer patients. MEDICAL HYPOTHESES , vol.63, no.4 , 684-687.

Altundag, O., Altundag, K., & Gunduz, M., (2004). DNA methylation inhibitor, procainamide, may decrease the tamoxifen resistance by inducing overexpression of the estrogen receptor beta in breast cancer patients. MEDICAL HYPOTHESES , vol.63, no.4, 684-687.

Altundag, O, K Altundag, And M Gunduz. "DNA methylation inhibitor, procainamide, may decrease the tamoxifen resistance by inducing overexpression of the estrogen receptor beta in breast cancer patients," MEDICAL HYPOTHESES , vol.63, no.4, 684-687, 2004

Altundag, O Et Al. "DNA methylation inhibitor, procainamide, may decrease the tamoxifen resistance by inducing overexpression of the estrogen receptor beta in breast cancer patients." MEDICAL HYPOTHESES , vol.63, no.4, pp.684-687, 2004

Altundag, O. Altundag, K. And Gunduz, M. (2004) . "DNA methylation inhibitor, procainamide, may decrease the tamoxifen resistance by inducing overexpression of the estrogen receptor beta in breast cancer patients." MEDICAL HYPOTHESES , vol.63, no.4, pp.684-687.

@article{article, author={O Altundag Et Al. }, title={DNA methylation inhibitor, procainamide, may decrease the tamoxifen resistance by inducing overexpression of the estrogen receptor beta in breast cancer patients}, journal={MEDICAL HYPOTHESES}, year=2004, pages={684-687} }